Breno José Alencar Pires Barbosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Breno José Alencar Pires Barbosa has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Caramelli
Behavioral and Cognitive Neurology Unit, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
19 shared publications - Sonia Maria Dozzi Brucki
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo – São Paulo, Brasil
19 shared publications - Jerusa Smid
Academia Brasileira de Neurologia, Brazil; Universidade de São Paulo, Brazil
17 shared publications - Leonardo Cruz de Souza
Universidade Federal de Minas Gerais
17 shared publications - Lucas Porcello Schilling
Pontifícia Universidade Católica do Rio Grande do Sul, Brazil
17 shared publications - Marcio Luiz Figueredo Balthazar
Laboratory of Imaging and Biomarkers in Cognitive Disorders, School of Medical Sciences, Universidade Estadual de Campinas
17 shared publications
Latest Publications
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11) , e218735
Prevalence and Profile of Undiagnosed Dementia in Brazil
Background and ObjectivesDementia underdiagnosis is a major barrier to public health strategies, particularly in low- and middle-income countries. Although Brazil has a high prevalence of dementia,...
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11) , e218735
Prevalence and Profile of Undiagnosed Dementia in Brazil
Background and ObjectivesDementia underdiagnosis is a major barrier to public health strategies, particularly in low- and middle-income countries. Although Brazil has a high prevalence of dementia,...
- Open Access
- 13 August 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (11) , 001-010
The entorhinal cortex atrophy score for diagnostic distinction between phases of the Alzheimer's disease continuum
Alzheimer's disease (AD) is the most common type of dementia, causing functional impairment in millions of individuals and accounting for a large amount of healthcare costs. The entorhinal cortex appears to be one of the first brain structures affected by AD in its early stages. The Entorhinal Cortex Atrophy (ERICA) score is a visual atrophy score used by neuroradiologists in clinical practice for the diagnosis of AD. To analyze the effectiveness of the ERICA score for distinguishing between patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD dementia. A systematic review of the literature was conducted on the Science Direct, PubMed, Virtual Health Library, and Cochrane databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Of 1,413 studies identified, 6 were ultimately included in the present review, comprising 844 participants: 2 retrospective cohort studies and 4 cross-sectional studies. The methodological quality of the studies was assessed using the Newcastle-Ottawa scale. The focus was on the diagnostic performance of the ERICA score in the continuum phases of AD. The ERICA score had lower sensitivity than the medial temporal lobe atrophy (MTA) score but higher specificity, reinforcing its importance for diagnostic accuracy, especially in contexts of clinical uncertainty. The ERICA score showed reproducibility between examiners similar to or greater than that of the MTA score. There are a few heterogeneous studies in the current literature on the applicability of the ERICA score in clinical practice. Diagnostic accuracy of the ERICA score is satisfactory in differentiating SCD or MCI from AD dementia.
- 13 August 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (11) , 001-010
Open AccessThe entorhinal cortex atrophy score for diagnostic distinction between phases of the Alzheimer's disease continuum
Alzheimer's disease (AD) is the most common type of dementia, causing functional impairment in millions of individuals and accounting for a large amount of healthcare costs. The entorhinal cortex appears to be one of the first brain structures affected by AD in its early stages. The Entorhinal Cortex Atrophy (ERICA) score is a visual atrophy score used by neuroradiologists in clinical practice for the diagnosis of AD. To analyze the effectiveness of the ERICA score for distinguishing between patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD dementia. A systematic review of the literature was conducted on the Science Direct, PubMed, Virtual Health Library, and Cochrane databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Of 1,413 studies identified, 6 were ultimately included in the present review, comprising 844 participants: 2 retrospective cohort studies and 4 cross-sectional studies. The methodological quality of the studies was assessed using the Newcastle-Ottawa scale. The focus was on the diagnostic performance of the ERICA score in the continuum phases of AD. The ERICA score had lower sensitivity than the medial temporal lobe atrophy (MTA) score but higher specificity, reinforcing its importance for diagnostic accuracy, especially in contexts of clinical uncertainty. The ERICA score showed reproducibility between examiners similar to or greater than that of the MTA score. There are a few heterogeneous studies in the current literature on the applicability of the ERICA score in clinical practice. Diagnostic accuracy of the ERICA score is satisfactory in differentiating SCD or MCI from AD dementia.
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (08) , 001-005
A challenging case of Down syndrome regression disorder
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (08) , 001-005
Open AccessA challenging case of Down syndrome regression disorder
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- Open Access
- 12 May 2026
- Vol. 84 (8) , 1-5
A challenging case of Down syndrome regression disorder.
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- 12 May 2026
- Vol. 84 (8) , 1-5
Open AccessA challenging case of Down syndrome regression disorder.
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- Open Access
- 27 April 2026
- Published by Springer Nature in Research on Biomedical Engineering
- Vol. 42 (2) , 29
GeronGnosis: a database for diagnosing dementias using EEG and machine learning
- 27 April 2026
- Published by Springer Nature in Research on Biomedical Engineering
- Vol. 42 (2) , 29
Open AccessGeronGnosis: a database for diagnosing dementias using EEG and machine learning
- 26 February 2026
- Published by Elsevier in Sleep Medicine
- Vol. 142, 108874
Non-pharmacological interventions for sleep disorders in patients with Alzheimer's disease: An integrative review
- 26 February 2026
- Published by Elsevier in Sleep Medicine
- Vol. 142, 108874
Non-pharmacological interventions for sleep disorders in patients with Alzheimer's disease: An integrative review
- Open Access
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20
A critical perspective of prion disease surveillance in Brazil
Introduction: Prion diseases (PrD) are a group of rapidly progressive dementias. Among its subtypes, Creutzfeldt-Jakob Disease (CJD) is the most common, affecting around 1–2 individuals per million inhabitants yearly. In 2005, Brazil’s Ministry of Health (MH) initiated a surveillance program for CJD, creating a protocol to report the cases. Despite advances, the MH still struggles to make a reliable database to determine PrD profile in Brazil. Therefore, the aim of the present study was to understand the Brazilian PrD surveillance system. Methods: This is a retrospective and descriptive study based on the epidemiological records of CJD surveillance from 2005 to 2021 in the Ministry of Health’s Epidemiological Bulletin published in 2022. Results: 1,576 suspected cases of CJD were reported, concentrated in the Southeast, South and Northeast regions of Brazil. Among the notifications, the following age groups predominated: 55–74 years (60.2%), 45–54 years (15%), and 75–85 years (11.8%). Suspected cases were mainly represented by women (53.6%), white individuals (61.4%), and residents of urban areas (90%). 547 cases (34.7%) were confirmed based on the following confirmation criteria: laboratory (65.6%), clinical-epidemiological (29.4%), and not informed (4.9%). Conclusion: In this period, the expected number of cases for the Brazilian population would be 3,200. Additionally to underreporting, the data shared by MH is limited due to the use of a database destined to mainly observe epidemic outbreaks and mismatches between official documents. Despite some progress since 2005, PrD surveillance in Brazil faces significant problems, due to the inaccurate treatment of these data and the lack of a specific database for CJD.
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20
Open AccessA critical perspective of prion disease surveillance in Brazil
Introduction: Prion diseases (PrD) are a group of rapidly progressive dementias. Among its subtypes, Creutzfeldt-Jakob Disease (CJD) is the most common, affecting around 1–2 individuals per million inhabitants yearly. In 2005, Brazil’s Ministry of Health (MH) initiated a surveillance program for CJD, creating a protocol to report the cases. Despite advances, the MH still struggles to make a reliable database to determine PrD profile in Brazil. Therefore, the aim of the present study was to understand the Brazilian PrD surveillance system. Methods: This is a retrospective and descriptive study based on the epidemiological records of CJD surveillance from 2005 to 2021 in the Ministry of Health’s Epidemiological Bulletin published in 2022. Results: 1,576 suspected cases of CJD were reported, concentrated in the Southeast, South and Northeast regions of Brazil. Among the notifications, the following age groups predominated: 55–74 years (60.2%), 45–54 years (15%), and 75–85 years (11.8%). Suspected cases were mainly represented by women (53.6%), white individuals (61.4%), and residents of urban areas (90%). 547 cases (34.7%) were confirmed based on the following confirmation criteria: laboratory (65.6%), clinical-epidemiological (29.4%), and not informed (4.9%). Conclusion: In this period, the expected number of cases for the Brazilian population would be 3,200. Additionally to underreporting, the data shared by MH is limited due to the use of a database destined to mainly observe epidemic outbreaks and mismatches between official documents. Despite some progress since 2005, PrD surveillance in Brazil faces significant problems, due to the inaccurate treatment of these data and the lack of a specific database for CJD.
- Open Access
- 11 December 2025
- Published by Universidade Federal de Pernambuco in Estudos Universitários
- Vol. 42 (1) , 1-42
Use of artificial intelligence in predicting cognitive decline and dementia: a systematic review
The use of Artificial Intelligence (AI) and Machine Learning (ML) has been applied in several studies to detect the conversion from mild cognitive impairment (MCI) to dementia. This study aims to identify challenges and effective methods for applying AI in predicting cognitive decline and dementia. A literature review was conducted by searching the PubMed database between May and July 2024, using predefined eligibility criteria. The analysis included 17 studies involving 12,183 participants (aged 50 to 85 years). The review included 17 articles published between 2015 and 2023, predominantly observational studies. The AI tools applied encompassed demographic and lifestyle data, imaging exams, cognitive tests, biomarkers, and physiological data. MCI was the most prevalent diagnosis among the studies, with a particular focus on the amnestic subtype. Nine studies investigated the conversion from MCI to some form of dementia; four analyzed the prediction of beta-amyloid positivity; three employed ML for diagnostic support in distinguishing controls from patients with different types of dementia; and one assessed the cognitive risk in an elderly population. Among the best-performing approaches identified, multimodal data strategies — especially those involving MRI imaging and sociodemographic information — stood out. Applications involving multimodal datasets, particularly those including MRI exams, improve the overall performance of ML models and are considered among the most effective approaches. Future research should focus on the diagnosis and prediction of less-studied dementias, such as frontotemporal dementia, through the use of AI. The integration of multimodal data, including demographic information, imaging exams, cognitive assessments, and biomarkers, should be encouraged.
- 11 December 2025
- Published by Universidade Federal de Pernambuco in Estudos Universitários
- Vol. 42 (1) , 1-42
Open AccessUse of artificial intelligence in predicting cognitive decline and dementia: a systematic review
The use of Artificial Intelligence (AI) and Machine Learning (ML) has been applied in several studies to detect the conversion from mild cognitive impairment (MCI) to dementia. This study aims to identify challenges and effective methods for applying AI in predicting cognitive decline and dementia. A literature review was conducted by searching the PubMed database between May and July 2024, using predefined eligibility criteria. The analysis included 17 studies involving 12,183 participants (aged 50 to 85 years). The review included 17 articles published between 2015 and 2023, predominantly observational studies. The AI tools applied encompassed demographic and lifestyle data, imaging exams, cognitive tests, biomarkers, and physiological data. MCI was the most prevalent diagnosis among the studies, with a particular focus on the amnestic subtype. Nine studies investigated the conversion from MCI to some form of dementia; four analyzed the prediction of beta-amyloid positivity; three employed ML for diagnostic support in distinguishing controls from patients with different types of dementia; and one assessed the cognitive risk in an elderly population. Among the best-performing approaches identified, multimodal data strategies — especially those involving MRI imaging and sociodemographic information — stood out. Applications involving multimodal datasets, particularly those including MRI exams, improve the overall performance of ML models and are considered among the most effective approaches. Future research should focus on the diagnosis and prediction of less-studied dementias, such as frontotemporal dementia, through the use of AI. The integration of multimodal data, including demographic information, imaging exams, cognitive assessments, and biomarkers, should be encouraged.
- Open Access
- 22 August 2025
- Published by Springer Nature in Research Square
GeronGnosis: A Database for Diagnosing Dementias Using EEG and Machine Learning
Proposal:The aging population has led to an increase in chronic degenerative diseases, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). Future projections indicate that this increase will be more pronounced, with cases tripling by 2025. Therefore, it is necessary to identify patterns of brain activity related to dementia to assist in earlier diagnosis. Objective: In this study, we propose to compare the performance of machine learning (ML) models across different databases in patients with dementia and elderly individuals using EEG data. Methods: We investigated various machine learning models using two distinct EEG databases: OpenNeuro (AD, FTD, and healthy controls) and GeronGnosis (mild cognitive impairment - MCI, AD, FTD, and healthy controls), the latter developed by the researchers and presented here for the first time. After extracting different signal attributes, we applied the Bayes Network, Random Tree, Random Forest, and SVM models and compared their best performances. Results: The Random Forest model with 500 trees demonstrated the best classification performance, achieving an accuracy of 98% on the GeronGnosis database, while the OpenNeuro database reached an accuracy of 95%. Conclusion: The GeronGnosis database was able to correctly classify patients with dementia and healthy controls with excellent performance across the studied metrics. Additionally, as a national and unprecedented database, it allows for better representation of the local population, helping to improve the clinical applicability of classification models.
- 22 August 2025
- Published by Springer Nature in Research Square
Open AccessGeronGnosis: A Database for Diagnosing Dementias Using EEG and Machine Learning
Proposal:The aging population has led to an increase in chronic degenerative diseases, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD). Future projections indicate that this increase will be more pronounced, with cases tripling by 2025. Therefore, it is necessary to identify patterns of brain activity related to dementia to assist in earlier diagnosis. Objective: In this study, we propose to compare the performance of machine learning (ML) models across different databases in patients with dementia and elderly individuals using EEG data. Methods: We investigated various machine learning models using two distinct EEG databases: OpenNeuro (AD, FTD, and healthy controls) and GeronGnosis (mild cognitive impairment - MCI, AD, FTD, and healthy controls), the latter developed by the researchers and presented here for the first time. After extracting different signal attributes, we applied the Bayes Network, Random Tree, Random Forest, and SVM models and compared their best performances. Results: The Random Forest model with 500 trees demonstrated the best classification performance, achieving an accuracy of 98% on the GeronGnosis database, while the OpenNeuro database reached an accuracy of 95%. Conclusion: The GeronGnosis database was able to correctly classify patients with dementia and healthy controls with excellent performance across the studied metrics. Additionally, as a national and unprecedented database, it allows for better representation of the local population, helping to improve the clinical applicability of classification models.
- Open Access
- 9 May 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (05) , 001-008
How the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil
Since the advent of 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG, henceforth, FDG) in the 1970s as a neurochemical tracer, FDG positron emission tomography (PET) has been used for research in dementia and to help diagnose dementing neurodegenerative disorders. However, FDG PET is still unavailable in most centers, especially those in low- and middle-income countries, and there is limited data on biomarkers from patients in diverse populations, such Latin Americans.To analyze the main indications and how the use of FDG PET helped improve the diagnosis of dementia in a specialized center in Recife, one of the largest cities in Northeastern Brazil.We retrospectively analyzed data from 62 individuals under follow-up at our center between 2018 and 2023 who had a clinical diagnosis of dementia or mild cognitive impairment and underwent FDG PET scans.In 21/29 (72.4%) patients, FDG PET helped investigate the types of atypical neurodegenerative dementias; in 14/24 (58.3%), it clarified the clinical question in the investigation of early-onset dementia syndromes; and, in 9 cases, it was performed to differentiate between degenerative and non-degenerative dementias.These numbers may set the foundation for further longitudinal analyses and collaborative studies including participants from Northeastern Brazil.
- 9 May 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (05) , 001-008
Open AccessHow the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil
Since the advent of 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG, henceforth, FDG) in the 1970s as a neurochemical tracer, FDG positron emission tomography (PET) has been used for research in dementia and to help diagnose dementing neurodegenerative disorders. However, FDG PET is still unavailable in most centers, especially those in low- and middle-income countries, and there is limited data on biomarkers from patients in diverse populations, such Latin Americans.To analyze the main indications and how the use of FDG PET helped improve the diagnosis of dementia in a specialized center in Recife, one of the largest cities in Northeastern Brazil.We retrospectively analyzed data from 62 individuals under follow-up at our center between 2018 and 2023 who had a clinical diagnosis of dementia or mild cognitive impairment and underwent FDG PET scans.In 21/29 (72.4%) patients, FDG PET helped investigate the types of atypical neurodegenerative dementias; in 14/24 (58.3%), it clarified the clinical question in the investigation of early-onset dementia syndromes; and, in 9 cases, it was performed to differentiate between degenerative and non-degenerative dementias.These numbers may set the foundation for further longitudinal analyses and collaborative studies including participants from Northeastern Brazil.